See more : Polyram Plastic Industries LTD (POLP.TA) Income Statement Analysis – Financial Results
Complete financial analysis of Ligand Pharmaceuticals Incorporated (LGNDV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ligand Pharmaceuticals Incorporated, a leading company in the Biotechnology industry within the Healthcare sector.
- Troika Media Group, Inc. (TRKAW) Income Statement Analysis – Financial Results
- Press Ventures, Inc. (PVEN) Income Statement Analysis – Financial Results
- Seven Bank, Ltd. (8410.T) Income Statement Analysis – Financial Results
- CIBL, Inc. (CIBY) Income Statement Analysis – Financial Results
- LeoVegas AB (publ) (LEO.ST) Income Statement Analysis – Financial Results
Ligand Pharmaceuticals Incorporated (LGNDV)
About Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is based in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 131.31M | 196.25M | 277.13M | 186.42M | 120.28M | 251.45M | 141.10M | 108.97M | 71.91M | 64.54M | 48.97M | 31.39M | 30.04M | 23.54M | 38.94M | 27.32M | 12.89M | 140.96M | 176.61M | 163.51M | 141.14M | 96.64M | 76.34M | 48.11M | 40.90M | 17.70M | 51.70M | 36.80M | 24.50M | 13.30M |
| Cost of Revenue | 35.05M | 52.83M | 62.18M | 30.42M | 11.35M | 6.34M | 5.37M | 5.57M | 5.81M | 9.14M | 5.73M | 3.60M | 4.91M | 0.00 | 15.24M | 0.00 | 0.00 | 22.64M | 39.85M | 39.80M | 31.62M | 20.31M | 13.95M | 1.62M | 3.10M | -7.70M | -9.80M | -9.40M | -3.70M | 24.70M |
| Gross Profit | 96.27M | 143.42M | 214.96M | 156.00M | 108.94M | 245.12M | 135.74M | 103.40M | 66.11M | 55.40M | 43.24M | 27.79M | 25.13M | 23.54M | 23.71M | 27.32M | 12.89M | 118.32M | 136.76M | 123.71M | 109.52M | 76.33M | 62.39M | 46.49M | 37.80M | 25.40M | 61.50M | 46.20M | 28.20M | -11.40M |
| Gross Profit Ratio | 73.31% | 73.08% | 77.56% | 83.68% | 90.57% | 97.48% | 96.20% | 94.89% | 91.93% | 85.84% | 88.29% | 88.53% | 83.66% | 100.00% | 60.88% | 100.00% | 100.00% | 83.94% | 77.44% | 75.66% | 77.60% | 78.99% | 81.73% | 96.64% | 92.42% | 143.50% | 118.96% | 125.54% | 115.10% | -85.71% |
| Research & Development | 24.54M | 36.08M | 69.01M | 59.39M | 55.91M | 27.86M | 26.89M | 21.22M | 13.38M | 12.12M | 9.27M | 10.79M | 10.29M | 22.07M | 39.87M | 30.77M | 44.62M | 41.93M | 56.08M | 65.20M | 67.68M | 58.81M | 51.10M | 51.29M | 59.40M | 70.70M | 72.40M | 59.50M | 41.40M | 0.00 |
| General & Administrative | 52.79M | 70.06M | 57.48M | 64.44M | 41.88M | 37.73M | 28.65M | 26.62M | 24.38M | 22.57M | 17.98M | 16.11M | 14.98M | 29.72M | 30.45M | 23.79M | 30.41M | 248.28M | 107.16M | 95.88M | 61.02M | 41.68M | 34.43M | 34.11M | 27.30M | 16.60M | 10.10M | 10.20M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -15.24M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 52.79M | 70.06M | 57.48M | 64.44M | 41.88M | 37.73M | 28.65M | 26.62M | 24.38M | 22.57M | 17.98M | 16.11M | 14.98M | 29.72M | 15.21M | 23.79M | 30.41M | 248.28M | 107.16M | 95.88M | 61.02M | 41.68M | 34.43M | 34.11M | 27.30M | 16.60M | 10.10M | 10.20M | 8.00M | 7.00M |
| Other Expenses | 7.00M | 34.24M | 9.57M | 23.44M | 16.86M | 15.79M | 12.12M | 10.64M | -10.03M | -3.19M | -2.14M | -2.79M | 0.00 | 0.00 | 0.00 | -1.96M | -1.96M | -3.12M | 78.05M | 62.03M | 50.53M | 16.69M | 0.00 | 6.97M | 7.40M | 7.70M | 9.80M | 9.40M | 3.70M | 2.50M |
| Operating Expenses | 84.32M | 140.38M | 136.06M | 147.27M | 114.66M | 81.39M | 67.66M | 58.49M | 37.76M | 34.69M | 27.26M | 26.90M | 25.27M | 51.79M | 70.32M | 52.59M | 73.07M | 287.09M | 163.23M | 161.08M | 128.70M | 100.49M | 85.53M | 92.37M | 94.10M | 95.00M | 92.30M | 79.10M | 53.10M | 9.50M |
| Cost & Expenses | 119.37M | 193.21M | 198.24M | 177.69M | 126.00M | 87.73M | 73.03M | 64.06M | 43.57M | 43.83M | 32.99M | 30.50M | 30.18M | 51.79M | 70.32M | 52.59M | 73.07M | 309.73M | 203.08M | 200.88M | 160.32M | 120.79M | 99.48M | 93.99M | 97.20M | 87.30M | 82.50M | 69.70M | 49.40M | 34.20M |
| Interest Income | 7.71M | 2.05M | 886.00K | 8.08M | 28.43M | 14.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 381.00K | 31.00K | 440.00K | 586.00K | 2.16M | 8.66M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 656.00K | 1.80M | 18.74M | 27.42M | 35.75M | 48.28M | 11.40M | 12.18M | 11.80M | 4.86M | 2.08M | 3.31M | 2.51M | 58.00K | 270.00K | 202.00K | 735.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 37.41M | 43.39M | 41.34M | 27.97M | 43.73M | 16.69M | 12.52M | 11.29M | 2.63M | 2.66M | 2.66M | 2.73M | 2.79M | 2.21M | 3.13M | 1.05M | 2.62M | 16.22M | 18.71M | 15.28M | 14.28M | 10.47M | 6.57M | 6.97M | 7.40M | 7.70M | 9.80M | 9.40M | 3.70M | 2.50M |
| EBITDA | 101.73M | 54.41M | 133.16M | 69.05M | 38.01M | 238.30M | 81.15M | 55.18M | 29.96M | 23.37M | 18.65M | 3.94M | 1.74M | -13.13M | -6.47M | -96.26M | -50.11M | -61.86M | -26.47M | -18.27M | -59.69M | -35.13M | -16.56M | -38.64M | -54.19M | -65.10M | -21.00M | -23.50M | -21.20M | -18.40M |
| EBITDA Ratio | 77.47% | 4.45% | 42.29% | 17.16% | -668.88% | 71.39% | 58.66% | 54.99% | 8.61% | 41.73% | 42.10% | 9.09% | -5.89% | -160.15% | -79.68% | 175.76% | -452.33% | -111.38% | -10.75% | -23.02% | 0.85% | -10.81% | -10.74% | -79.16% | -105.62% | -106.78% | 77.95% | -73.91% | 51.43% | -96.99% |
| Operating Income | 11.94M | -25.50M | 78.90M | 8.55M | -5.72M | 163.73M | 68.08M | 43.89M | 27.33M | 19.63M | 14.94M | 574.00K | -698.00K | -29.30M | -9.97M | -97.28M | -60.18M | -168.77M | -26.47M | -37.37M | -19.18M | -24.15M | -23.14M | -45.88M | -56.30M | -69.60M | -30.80M | -32.90M | -24.90M | -20.90M |
| Operating Income Ratio | 9.09% | -13.00% | 28.47% | 4.59% | -4.76% | 65.11% | 48.25% | 40.27% | 38.00% | 30.41% | 30.51% | 1.83% | -2.32% | -124.50% | -25.60% | -356.13% | -466.69% | -119.73% | -14.99% | -22.86% | -13.59% | -24.99% | -30.31% | -95.37% | -137.65% | -393.22% | -59.57% | -89.40% | -101.63% | -157.14% |
| Total Other Income/Expenses | 51.72M | 32.97M | -31.65M | -36.38M | -10.44M | 9.60M | -10.85M | -35.93M | 8.00M | -8.32M | -5.74M | -4.44M | -2.86M | 13.90M | 95.00K | -239.00K | 6.72M | -96.19M | -9.87M | -7.54M | -20.39M | -8.36M | -8.36M | -825.00K | -707.00K | -43.00M | -61.30M | 3.70M | -33.80M | -5.50M |
| Income Before Tax | 63.66M | 36.01M | 47.30M | -10.54M | 796.64M | 173.33M | 57.23M | 7.96M | 35.33M | 11.30M | 9.21M | -3.87M | -2.93M | -15.40M | -9.87M | -97.52M | -53.46M | -174.27M | 36.34M | -44.91M | -37.46M | -32.60M | -31.50M | -46.71M | -62.00M | -112.60M | -92.10M | -29.20M | -58.70M | -26.40M |
| Income Before Tax Ratio | 48.48% | 18.35% | 17.07% | -5.65% | 662.31% | 68.93% | 40.56% | 7.30% | 49.13% | 17.51% | 18.80% | -12.31% | -9.75% | -65.44% | -25.35% | -357.00% | -414.58% | -123.63% | 20.58% | -27.46% | -26.54% | -33.73% | -41.26% | -97.08% | -151.59% | -636.16% | -178.14% | -79.35% | -239.59% | -198.50% |
| Income Tax Expense | 9.84M | 41.23M | -10.29M | -7.55M | 167.34M | 30.01M | 44.68M | 10.33M | -219.60M | 410.00K | 374.00K | -1.19M | -13.10M | -2.62M | -7.92M | -55.00K | -18.70M | -38.41M | 59.00K | 233.00K | 18.28M | 8.45M | 19.86M | 26.49M | 18.40M | 48.30M | 69.40M | 4.40M | 39.30M | 6.20M |
| Net Income | 52.15M | -5.22M | 57.14M | -2.99M | 629.30M | 143.32M | 12.56M | -1.64M | 257.31M | 12.02M | 11.42M | -527.00K | 10.18M | -12.52M | -1.95M | -98.11M | 281.69M | -31.74M | -36.40M | -45.14M | -37.46M | -32.60M | -43.00M | -72.38M | -74.70M | -117.90M | -100.20M | -37.30M | -64.20M | -27.10M |
| Net Income Ratio | 39.72% | -2.66% | 20.62% | -1.60% | 523.19% | 57.00% | 8.90% | -1.50% | 357.80% | 18.63% | 23.32% | -1.68% | 33.88% | -53.17% | -5.00% | -359.19% | 2,184.64% | -22.52% | -20.61% | -27.61% | -26.54% | -33.73% | -56.32% | -150.44% | -182.64% | -666.10% | -193.81% | -101.36% | -262.04% | -203.76% |
| EPS | 3.02 | -0.31 | 3.44 | -0.18 | 33.13 | 5.96 | 0.60 | -0.08 | 13.00 | 0.59 | 0.56 | -0.03 | 0.52 | -0.64 | -0.10 | -6.16 | 17.22 | -2.36 | -2.95 | -3.68 | -3.18 | -2.83 | -4.34 | -7.80 | -9.51 | -17.51 | -18.15 | -7.78 | -17.19 | -9.42 |
| EPS Diluted | 2.94 | -0.31 | 3.31 | -0.18 | 31.85 | 5.96 | 0.53 | -0.08 | 12.12 | 0.56 | 0.55 | -0.03 | 0.52 | -0.64 | -0.10 | -6.16 | 17.22 | -2.36 | -2.95 | -3.68 | -3.18 | -2.83 | -4.34 | -7.80 | -9.51 | -17.51 | -18.15 | -7.78 | -17.19 | -9.42 |
| Weighted Avg Shares Out | 17.30M | 16.87M | 16.63M | 16.18M | 19.00M | 24.05M | 21.03M | 20.83M | 19.79M | 20.42M | 20.31M | 19.10M | 19.66M | 19.61M | 18.86M | 15.92M | 16.35M | 13.44M | 12.34M | 12.28M | 11.78M | 11.52M | 9.90M | 9.28M | 7.86M | 6.73M | 5.52M | 4.80M | 3.73M | 2.88M |
| Weighted Avg Shares Out (Dil) | 17.76M | 16.87M | 17.25M | 16.18M | 19.76M | 24.07M | 23.48M | 20.83M | 21.23M | 21.43M | 20.75M | 19.85M | 19.71M | 19.61M | 18.86M | 15.92M | 16.35M | 13.44M | 12.34M | 12.28M | 11.78M | 11.52M | 9.90M | 9.28M | 7.86M | 6.73M | 5.52M | 4.80M | 3.73M | 2.88M |
Source: https://incomestatements.info
Category: Stock Reports